Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Regeneron Pharmaceuticals (REGN)

Regeneron expects $102 million Q1 2026 IPR&D charge, cutting EPS by $0.81

Negative Impact 3 of 5 earnings Written later

Regeneron said its first-quarter 2026 GAAP and non-GAAP results will include an acquired in-process research and development charge of about $102 million pre-tax. The charge mainly reflects premiums on equity securities purchased and milestone and up-front payments under collaboration and licensing agreements, and is expected to reduce net income per diluted share by about $0.81. The figures are preliminary and unaudited, and the final results may differ.

Key points

  • Expected acquired IPR&D charge: about $102 million pre-tax for the quarter ended March 31, 2026
  • Expected impact: about $0.81 reduction in GAAP and non-GAAP net income per diluted share
  • Charge relates to equity securities premiums and collaboration and licensing payments; Regeneron does not forecast such charges

The filing

CompanyRegeneron Pharmaceuticals (REGN)
Form8-K, current report
Filed with the SECApr 8, 2026, 7:05 AM ET
Accession number0001104659-26-040661

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.